

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

**Segment wise Revenue, Results and Capital Employed,
under Clause 41 of the Listing Agreement**

(Rs. lakhs)

	Unaudited		Audited
	3 months ended 31.03.2005	3 months ended 31.03.2004	Year ended 31.12.2004
1. Segment Revenue:			
a) Pharmaceuticals	23589	31768	117672
b) Other Businesses	4468	4588	22090
Total Segment Revenue	28057	36356	139762
Less: Inter Segment Revenue	-	-	-
Net Sales / Income from Operations	28057	36356	139762
2. Segment Results (Profit before Interest and Tax):			
a) Pharmaceuticals	7154	10077	36896
b) Other Businesses	523	656	4710
Total Segment Results	7677	10733	41606
Add/(Less):			
(i) Interest Income (net)	548	803	2668
(ii) Unallocable Expenditure Net of Unallocable Income	(130)	(593)	(2450)
Total Profit Before Tax and Exceptional Items	8095	10943	41824
3. Capital Employed (Segment Assets less Segment Liabilities):			
a) Pharmaceuticals	19472	17955	14780
b) Other Businesses	8315	8583	8950
Total Capital Employed in Segments	27787	26538	23730

Notes:

1 Refer note 5 of the unaudited financial results for the quarter ended 31st March, 2005.

2 (i) The Company is organised into two main business segments, namely:

- Pharmaceuticals - comprising of bulk drugs and formulations
- Others - primarily comprising of veterinary formulations, feed supplements, fine chemicals, diagnostics, laboratory equipment and exports mainly relating to pharmaceuticals.

Segments have been identified and reported taking into account, the nature of products and services, the differing risks and returns, the organisation structure, and the internal financial reporting systems.

(ii) Segment Revenue in each of the above domestic business segments primarily includes sales (net of excise duty), processing charges, consignment sales commission, clinical data management and export incentives in the respective segments.

(iii) Segment Revenue, Results, Assets and Liabilities include the respective amounts identifiable to each of the segments and amounts allocated on a reasonable basis.